The treatment of Glioblastoma Xenografts by surfactant conjugated dendritic nanoconjugates
Source abstract
Abstract
Polysorbate 80 (P80) anchored poly(propyleneimine) (PPI) dendritic nanoconjugate was developed and evaluated for targeting anti-cancer drug, docetaxel (DTX) to the brain tumor. In vitro cytotoxicity studies of free DTX, DTX-PPI and DTX-P80-PPI dendrimers were carried out using U87MG human glioblastoma cell line. The in vivo anti-cancer activity in brain tumor bearing rats revealed that DTX loaded P80 conjugated dendrimers reduced the tumor volume extremely significantly (p < 0.0001; more than 50%). The median survival time for brain tumor bearing rats treated with DTX-P80-PPI dendrimers (42 days) was extended very significantly as compared to DTX-PPI (23 days; p < 0.001), receptor blocked group (15 days; p < 0.001) and free DTX (18 days; p < 0.001). Gamma scintigraphy and biodistribution studies further confirmed the targeting efficiency and higher biodistribution of ligand conjugated dendrimer into the brain. The results concluded that the developed nanoconjugate has potential to deliver significantly higher amount of drug to brain tumor for improved therapeutic outcome.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Dendrimers and Hyperbranched Polymers · RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (29)
Show source-provided references
1. Barriers to carrier mediated drug and gene delivery to brain tumors10.1016/j.jconrel.2005.09.053 ↗
2. Anderson symptom inventory brain tumor module (MDASI-BT)10.1007/s11060-006-9135-z ↗
3. Primary brain tumours in adults10.1016/S0140-6736(03)12328-8 ↗
4. Clinical cancer advances 2007: major research advances in cancer treatment, prevention and, screening- a report from the American society of clinical oncology10.1200/JCO.2008.21.2134 ↗
5. Drug interactions at blood-brain barrier: fact or fantasy?10.1016/j.pharmthera.2009.03.017 ↗
6. Active targeting of brain tumors using nanocarriers10.1016/j.biomaterials.2007.06.011 ↗
7. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals10.1016/j.jconrel.2009.09.020 ↗
8. Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders10.3109/10611861003639796 ↗
9. Targeted delivery of methotrexate to epidermal growth factor receptor–positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates10.1158/1535-7163.MCT-05-0325 ↗
10. Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro10.1163/156856209X415828 ↗
11. Pharmaceutical and biomedical potential of PEGylated dendrimers10.2174/138161207780162999 ↗
12. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex10.1016/j.addr.2005.09.014 ↗
13. Dendrosome-based gene delivery
14. Polypropylene imine dendrimer mediated solubility enhancement: effect of pH and functional groups of hydrophobes
15. Nano-sized MRI contrast agents with dendrimer cores10.1016/j.addr.2005.09.016 ↗
16. Dendrimers as therapeutic agents: a systematic review10.1211/jpp.61.08.0002 ↗
17. Dendrimers in oncology: an expanding horizon10.1021/cr068212n ↗
18. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer10.1016/j.bbagen.2006.12.007 ↗
19. Solid lipid nanoparticles for targeted brain drug delivery10.1016/j.addr.2007.04.011 ↗
20. PEGylated PPI dendritic architectures for sustained delivery of anti-inflammatory agent10.2174/157341308785161136 ↗
21. Novel PEGylated nanoparticulate architectures for sustained delivery of H2 receptor antagonist10.1016/j.ejmech.2008.06.012 ↗
22. Preparation of an imidazole-conjugated oligonucleotide10.1021/bc000004t ↗
23. Investigation on biodistribution of technetium-99m-labeled carbohydrate-caoted poly(propylene imine) dendrimers10.1016/j.nano.2007.02.002 ↗
24. Brain tumor tendem targeting using a combination of monoclonal antibodies attached to biopoly(β-L-malic acid)10.1016/j.jconrel.2007.05.032 ↗
25. PK and tissue distribution of docetaxel in rabitts after i.v. administration of liposomal and injectable formulations10.1016/j.jpba.2009.01.016 ↗
26. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells10.1016/j.ijpharm.2010.04.002 ↗
27. Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone10.1016/S0360-3016(98)00374-5 ↗
28. Improved penetration of docetaxel into brain by co-administration of inhibitors of P-glycoprotein10.1016/j.ejca.2004.01.024 ↗
29. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier10.1080/10611860290031877 ↗